Search

Displaying results 5051 - 5060 of 10000 in total
  1. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  2. Drug

    Carthamus tinctorius flower bud

    go.drugbank.com/drugs/DB14278
    Approved

    Carthamus tinctorius flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Zanthoxylum clava-herculis whole

    go.drugbank.com/drugs/DB14353
    Approved

    Zanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    Ranpirnase is a ribonuclease enzyme found in <i>Rana pipiens</i> oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. … It is the first ribonuclease to enter cancer clinical trials.

  5. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  6. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

  7. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  8. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in

  9. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib in myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (active, not recruiting

  10. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.